

16/24

1/24

Met Glu Asp Thr Lys Glu Ser Asn Val Lys Thr Phe Cys Ser Lys Asn Ile Leu Ala 19
Ile Leu Gly Phe Ser Ser Ile Ile Ala Val Ile Ala Leu Leu Ala Val Gly Leu Thr 38
Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser 57
Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly 76
Val Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val 95
Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu 114
Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly 133
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val 152
Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly 171
Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser 190
Gln Lys Thr Arg Trp Phe Ser Ile Val Pro Tyr Glu Thr Asn Asn Gln Glu Thr Phe 209
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gln Asn Gln 228
Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn 247
Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu 266
Ala Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro 285
Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg 304
Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln 323
Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln 342
Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser 361
Ala Phe Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu 380
Lys Val Thr Glu Met Met Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr 399
Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Tyr 418
Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Trp Glu His Ile 437
His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu 456
Asn Leu Thr Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser 475
Thr Tyr Val Phe Leu Met Val Leu Phe Ser Leu Val Leu Phe Thr Val Ala Ile Ile 494
Gly Leu Leu Ile Phe His Lys Pro Ser Tyr Phe Trp Lys Asp Met Val 510

Fig. 1

POSTER NUMBER 360

11/08/91
2 of 24

2/24

PROTEIN DOMAIN DIAGRAM




Fig. 2

May 8 2014
3g/24

3/24




Fig. 3

5/10/2014
4 of 24

4/24




Fig. 4

9/85, 141
5 of 24




Fig. 5A

F002 F4100 234 T55 E36 D0




Fig. 5C

5/18/85, 14/
6 of 24

6/24




Fig. 5B

07/05/14
7 of 24

7/24




Fig. 6A




Fig. 6B

57/08/14
8 of 24

8/24

Printed 2014 Feb 26 0




Fig. 7A

Fig. 7B

04/02/85, 14/1
9 of 24

9/24




Fig. 8A

04/02/85, 14/1




Fig. 8B




Fig. 8C

57/450, 147
10 of 24

10/24




Fig. 9A




Fig. 9B




Fig. 9C

04/18/85, 14/
11 of 24

11/24

DEPARTMENT OF BIOLOGY




Fig. 10




Fig. 11

5/18/03, 14/
12 of 24

12/24

Aspirin Baseline

Aspirin at Day 5




Fig. 12A

T DOSE-HD.2411232000

High Dose CD39

Baseline

Day 7




Fig. 12B

04/18/88, 141
13 of 24

13/24




Fig. 13

TOEPLITZ CHIEF




Fig. 14

07/823,14)
14 of 24

14/24




Fig. 15A




Fig. 15B




Fig. 15C

5/18/92, 14/1
15 of 24

15/24




Fig. 16




Fig. 17A

16 of 24

16/24




Fig. 17B

59/835, 147
17 of 24

17/24




Fig. 18A

FIGURE 18. Effects of solCD39




Fig. 18B




Fig. 18C

09/828, 147
18 of 24

18/24




Fig. 18D




Fig. 18E

09/855, 14 |
19 of 24

19/24




Fig. 19

PROTOKOL ZITTEGÖ




Fig. 20A

09/835, 147
20 of 24

21/24

POST-THROMBOLYTIC




Fig. 21

09/88, 14/
21 of 24

20/24




Fig. 20B

09/89, 14/
22 of 24

22/24




Fig. 22A




Fig. 22B




Fig. 22C

23/24




Fig. 22D




Fig. 22E

1/10/14
24 of 24

24/24




Fig. 23

F U N D A M E N T A L T E C H N O L O G Y

Human CD39 (amino acids 1-69 of SEQ ID NO:2)
MEDTKESNVK TFC SKNILAI LGF SII AVI ALLA VGL TQ M KALP ENVK YG IVLD AGSS...
| || | ||||
MATS WGT VFF MLVV SVC CSA VSH RN QQT WF EGIF LSS MCP IN VS A STLY G IMF DAG ST...
Human CD39-L4 (SEQ ID NO:31)

Fig. 24